Nundina › Discover calendars › FDA New Drug Approvals calendar › FDA approves Pasatru (garetosmab-grts)FDA approves Pasatru (garetosmab-grts)19 August 2026The FDA approved Pasatru (garetosmab-grts), a biologic from Regeneron Pharmaceuticals, Inc. Form: Injectable, Intravenous. Granted priority review, reserved for treatments that would be a significant improvement over what exists. Application BLA761508.FDA New Drug Approvals calendarMore from this calendar

19 October 2026 - FDA approves Calrezdy (calcuim chloride)

19 October 2026 - FDA approves Cienby (sodium ctirate)

16 October 2026 - FDA approves Yulzety (rivaroxaban)

16 October 2026 - FDA approves Brytly (brytly (apraclonidine))

15 October 2026 - FDA approves Evoxac (cevimeline hydrochloride)